LA MIRADA, CA--(Marketwire - Feb 19, 2013) - BioLargo, Inc. (
Nature's Best Solution® products use BioLargo's patented technology consisting of a proprietary blend of micronutrients essential to life. Nature's Best Solution® FREE IODINE Wound and Skin products are non-cytotoxic, contain no steroids or antibiotics, and do not stain, sting or produce offensive odors.
The debuting product line includes:
- Nature's Best Solution® Litter Box Deodorizing Concentrate
- Nature's Best Solution® Stain & Odor Eliminator
- Nature's Best Solution® Litter Box Odor Eliminator
- Natures' Best Solution® Litter Box Wipes
- Nature's Best Solution® FREE IODINE Wound and Skin Solutions
"Given the broad application of our technology, expanding our product offering to include the Nature's Best Solution® brand allows us to incorporate our technology into a broad range of consumer products," said Dennis Calvert, BioLargo's president. "Focusing on pets first made sense because of our prior experience in the equine market. Pets and pet owners will benefit because Nature's Best Solution® products work better than existing products."
In its ninth year, Global Pet Expo 2013 is expected to attract more than 5,000 buyers and distributors. The show is open to independent retailers, distributors, mass-market buyers and other qualified pet industry professionals.
For more information about the Nature's Best Solution® Pet Care Line visit www.NaturesBestSolution.com.
About BioLargo, Inc.
We make life better by delivering technology-based products that help solve some of the world's most important problems that threaten our water, food, agriculture, healthcare and energy. Our website is www.BioLargo.com. Our Odor-No-More Inc. subsidiary features award-winning products serving the companion animal and equine markets, including the Nature's Best Solution® and Deodorall® brands. (www.OdorNoMore.com). BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project. Our subsidiary, Clyra Medical Technologies, Inc., focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2013.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2011.